25C-NBOMe: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[File:2C-C-NBOMe.gif|2C-C-NBOMe|thumb]] [[File:25C-NBOMe_blotter.jpg|25C-NBOMe blotter|thumb|left]] | [[File:2C-C-NBOMe.gif|2C-C-NBOMe|thumb]] [[File:25C-NBOMe_blotter.jpg|25C-NBOMe blotter|thumb|left]] | ||
{{Short description|Psychedelic drug}} | {{Short description|Psychedelic drug}} | ||
{{Drugbox | {{Drugbox | ||
| Line 12: | Line 11: | ||
| width2 = 200px | | width2 = 200px | ||
<!--Clinical data-->| tradename = | <!--Clinical data--> | ||
| tradename = | |||
| legal_status = | | legal_status = | ||
| legal_BR = F2 | | legal_BR = F2 | ||
| legal_BR_comment = | | legal_BR_comment = | ||
| legal_DE = Anlage I | | legal_DE = Anlage I | ||
| legal_US = Schedule I | | legal_US = Schedule I | ||
| legal_UK = Class A | | legal_UK = Class A | ||
| legal_UN = P I | | legal_UN = P I | ||
| legal_UN_comment = | | legal_UN_comment = | ||
<!--Identifiers-->| CAS_number_Ref = | <!--Identifiers--> | ||
| CAS_number_Ref = | |||
| CAS_number = 1227608-02-7 | | CAS_number = 1227608-02-7 | ||
| UNII_Ref = | | UNII_Ref = | ||
| UNII = 9FGW3C260N | | UNII = 9FGW3C260N | ||
| PubChem = 46856354 | | PubChem = 46856354 | ||
| KEGG_Ref = | | KEGG_Ref = | ||
| KEGG = C22720 | | KEGG = C22720 | ||
| ChemSpiderID_Ref = | | ChemSpiderID_Ref = | ||
| ChemSpiderID = 24583389 | | ChemSpiderID = 24583389 | ||
<!--Chemical data-->| C = 18 | <!--Chemical data--> | ||
| C = 18 | |||
| H = 22 | | H = 22 | ||
| Cl = 1 | | Cl = 1 | ||
| Line 38: | Line 40: | ||
| O = 3 | | O = 3 | ||
| smiles = COc2ccccc2CNCCc(cc1OC)c(OC)cc1Cl | | smiles = COc2ccccc2CNCCc(cc1OC)c(OC)cc1Cl | ||
| StdInChI_Ref = | | StdInChI_Ref = | ||
| StdInChI = 1S/C18H22ClNO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3 | | StdInChI = 1S/C18H22ClNO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3 | ||
| StdInChIKey_Ref = | | StdInChIKey_Ref = | ||
| StdInChIKey = FJFPOGCVVLUYAQ-UHFFFAOYSA-N | | StdInChIKey = FJFPOGCVVLUYAQ-UHFFFAOYSA-N | ||
}} | }} | ||
Latest revision as of 01:05, 31 March 2025
Psychedelic drug
| 25C-NBOMe | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1227608-02-7 |
| PubChem | 46856354 |
| DrugBank | |
| ChemSpider | 24583389 |
| KEGG | C22720 |
25C-NBOMe is a synthetic psychedelic compound that belongs to the NBOMe series of psychedelic drugs. It is chemically related to 2C-C (4-chloro-2,5-dimethoxyphenethylamine) from the 2C family of psychedelics which are part of the larger group of phenethylamine derivatives. 25C-NBOMe was first synthesized and studied by Ralf Heim at the Free University of Berlin in 2003. It acts primarily as a potent agonist for the 5-HT2A receptor, leading to its psychedelic effects.
Chemistry[edit]
25C-NBOMe is a derivative of the phenethylamine psychedelic 2C-C. It is specifically modified by adding a methoxybenzyl (NBOMe) group to the nitrogen (N) of the ethyl chain of 2C-C. This modification significantly increases its potency compared to its parent compound. The full chemical name of 25C-NBOMe is 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine.
Pharmacology[edit]
The primary mechanism of action of 25C-NBOMe involves its function as an agonist at the 5-HT2A receptor. The activation of this receptor is responsible for the compound's psychedelic effects. 25C-NBOMe has been found to be extremely potent, with active doses in the microgram range, making it significantly more potent than other classical psychedelics such as LSD or psilocybin.
Effects[edit]
The effects of 25C-NBOMe can vary greatly and can include both physical and psychological effects. Physical effects may include nausea, vasoconstriction, increased heart rate, and increased blood pressure. Psychological effects can include visual and auditory hallucinations, altered perception of time and space, euphoria, and introspection. The effects can last anywhere from 6 to 10 hours, depending on the dose and individual metabolism.
Risks and Safety[edit]
Due to its high potency and narrow therapeutic index, 25C-NBOMe has been associated with several adverse events, including fatalities. The risks of overdose and poisoning are significantly higher compared to traditional psychedelics. Symptoms of overdose may include severe agitation, cardiac arrest, and seizures. As a result, there is a high potential for harm when using substances like 25C-NBOMe, especially without precise dosing.
Legal Status[edit]
The legal status of 25C-NBOMe varies by country, but it has been banned or controlled in several jurisdictions due to concerns over its safety and potential for abuse. In some countries, it is classified as a controlled substance, making its possession, sale, or manufacture illegal.
Analogues and derivatives[edit]
Analogues and derivatives of 2C-C:
25C-NB*:
- 25C-NBF
- 25C-NBMD
- 25C-NBOH
- 25C-NBOMe (NBOMe-2CC)
- 25C-NB3OMe
- 25C-NB4OMe
- N-(2C-C)-fentanyl<ref>
Explore N-(2C-C)-Fentanyl | PiHKAL · info(link). isomerdesign.com.
</ref>
| Serotonin receptor modulators | ||||||
|---|---|---|---|---|---|---|
|
| Phenethylamines | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
